1. Home
  2. BCE vs UTHR Comparison

BCE vs UTHR Comparison

Compare BCE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BCE Inc.

BCE

BCE Inc.

HOLD

Current Price

$25.62

Market Cap

24.3B

Sector

N/A

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$536.15

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCE
UTHR
Founded
1880
1996
Country
Canada
United States
Employees
40390
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3B
23.9B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
BCE
UTHR
Price
$25.62
$536.15
Analyst Decision
Hold
Buy
Analyst Count
2
14
Target Price
$29.50
$531.79
AVG Volume (30 Days)
2.6M
466.2K
Earning Date
01-01-0001
05-28-2026
Dividend Yield
4.94%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$3.80
$7.77
Revenue Next Year
$1.33
$11.11
P/E Ratio
$5.19
$19.12
Revenue Growth
N/A
2.38
52 Week Low
$20.28
$266.98
52 Week High
$26.52
$548.12

Technical Indicators

Market Signals
Indicator
BCE
UTHR
Relative Strength Index (RSI) 46.38 61.74
Support Level $22.59 $464.92
Resistance Level $26.02 N/A
Average True Range (ATR) 0.44 19.31
MACD -0.10 4.68
Stochastic Oscillator 2.55 85.60

Price Performance

Historical Comparison
BCE
UTHR

About BCE BCE Inc.

BCE provides wireless, broadband, television, and landline phone services in Canada. It is one of the Big Three national wireless carriers, with over 10 million customers constituting about 30% of the market. It is also the incumbent local exchange carrier—the legacy telephone provider—throughout much of the eastern half of Canada, including in the most populous Canadian provinces: Ontario and Quebec. BCE has a media segment that holds television, radio, and digital media assets. BCE licenses the Canadian rights to HBO Max and Starz.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: